Um estudo para avaliar a eficácia e a segurança de Rozanolixizumabe em participantes adultos com doença associada a anticorpos de glicoproteína de oligodendrócitos de mielina (MOG) (MOG-AD) (cosMOG)
Um estudo randomizado, duplo-cego, controlado por placebo, multicêntrico, fase 3, estudo principal com um período de extensão aberto para avaliar a eficácia e a segurança de rozanolixizumabe em participantes adultos com doença associada a anticorpos de glicoproteína de oligodendrócitos (MOG) de mielina (MOG- DE ANÚNCIOS)
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Göttingen, Alemanha
- Mog001 40140
-
Münster, Alemanha
- Mog001 40177
-
-
-
-
-
Melbourne, Austrália
- Mog001 30022
-
-
-
-
-
Porto Alegre, Brasil
- Mog001 60033
-
-
-
-
-
Ghent, Bélgica
- Mog001 40185
-
-
-
-
-
Goyang-si, Coréia do Sul
- Mog001 20226
-
-
-
-
-
Barcelona, Espanha
- Mog001 40267
-
Madrid, Espanha
- Mog001 40161
-
Murcia, Espanha
- Mog001 40350
-
Málaga, Espanha
- Mog001 40341
-
Seville, Espanha
- Mog001 40049
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259-5452
- Mog001 50297
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Mog001 50450
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Mog001 50101
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20057
- Mog001 50553
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Mog001 50308
-
-
Illinois
-
Peoria, Illinois, Estados Unidos, 61637
- Mog001 50472
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Mog001 50552
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114-3117
- Mog001 50243
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mog001 50104
-
-
Texas
-
San Antonio, Texas, Estados Unidos, 78229
- Mog001 50568
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Mog001 50473
-
-
-
-
-
Strasbourg, França
- Mog001 40170
-
-
-
-
-
Athens, Grécia
- Mog001 40850
-
-
-
-
-
Pavia, Itália
- Mog001 40146
-
Roma, Itália
- Mog001 40629
-
Verona, Itália
- Mog001 40646
-
-
-
-
-
Chiba, Japão
- Mog001 20068
-
Isehara, Japão
- Mog001 20307
-
Kitakyushu-shi, Japão
- Mog001 20049
-
Kodaira, Japão
- Mog001 20143
-
Koriyama-shi, Japão
- Mog001 20223
-
Sendai, Japão
- Mog001 20224
-
Sendai, Japão
- Mog001 20227
-
Shinjuku-ku, Japão
- Mog001 20070
-
Suita-shi, Japão
- Mog001 20032
-
-
-
-
-
Culiacán, México
- Mog001 50486
-
Mexico City, México
- Mog001 50485
-
-
-
-
-
Bydgoszcz, Polônia
- Mog001 40840
-
-
-
-
-
Coimbra, Portugal
- Mog001 40485
-
Porto, Portugal
- Mog001 40669
-
-
-
-
-
Liverpool, Reino Unido
- Mog001 40661
-
Oxford, Reino Unido
- Mog001 40163
-
-
-
-
-
Huddinge, Suécia
- Mog001 40663
-
-
-
-
-
Basel, Suíça
- Mog001 40723
-
Bern, Suíça
- Mog001 40337
-
Zurich, Suíça
- Mog001 40630
-
-
-
-
-
Hradec Králové, Tcheca
- Mog001 40195
-
Teplice, Tcheca
- Mog001 40721
-
-
-
-
-
Istanbul, Turquia (Türkiye)
- Mog001 40550
-
Izmir, Turquia (Türkiye)
- Mog001 40726
-
Samsun, Turquia (Türkiye)
- Mog001 40648
-
Sancaktepe, Turquia (Türkiye)
- Mog001 40725
-
-
-
-
-
Kyiv, Ucrânia
- Mog001 20319
-
Ternopil, Ucrânia
- Mog001 20228
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Participant must be ≥18 to ≤89 years of age, at the time of signing the informed consent
- Confirmed diagnosis of MOGAD consistent with published diagnostic criteria for MOGAD
- Participant has history of relapsing MOGAD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization
- Participant must be clinically stable at the time of the Screening Visit and during the Screening Period
Exclusion Criteria:
- Participant has been diagnosed with a neurological autoimmune disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant
- Participant has a clinically important active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the investigational medicinal product (IMP)
- Participant has a current or medical history of primary immunodeficiency
- Participant tests positive for aquaporin-4 antibodies at Screening
- Participant has a serum total IgG level ≤ 5.5g/L
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Rozanolixizumab Arm
Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints. |
Participants will receive pre-specified doses of rozanolixizumab.
Outros nomes:
|
|
Comparador de Placebo: Placebo Arm
Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding. |
Participants will receive placebo.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period
Prazo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The TTFR (days) will be defined as the interval between the date of randomization and the first date of the objective relapse. During the Double Blind (DB) Treatment Period (Part A); EDB/EWD = End of Double-Blind/Early Withdrawal Visit |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period
Prazo: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Open-Label Extension (OLE) Treatment Period (Part B); EOS/EWD = End of Study/Early Withdrawal Visit. |
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
|
For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period
Prazo: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported. |
OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
For Part A: Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit
Prazo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
Visual acuity is a measurement of the capacity for visual discrimination of fine details. Visual acuity tests are used to determine the smallest characters that can be read on a standardized chart. The Landolt C Broken Ring Chart uses standardized incomplete rings or "C", which are positioned in any direction in the chart (up, down, left, right, and 45 degree positions in between). The participant has to be able to indicate where the break of the "C" is located, by describing the position or by giving gesture. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the EDB/EWD Visit (with confirmation at 3 months)
Prazo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments with half steps from 1.0 to 9.5. The higher the value the higher is the level of impairment and disability. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Number of MOGAD related inpatient hospitalizations during the DB Treatment Period
Prazo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
The total number of MOGAD related hospitalizations from Baseline through EDB/EWD Visit. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part A: Incidence of treatment-emergent adverse events (TEAEs) during the DB Treatment Period
Prazo: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. |
Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)
|
|
For Part B: Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period
Prazo: Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
An ARR will be calculated for each participant prior to randomization into the Double-Blind Treatment Period (based on available historical data), and 2 ARRs after randomization to study treatment: first for relapses occurring during the Double-Blind Treatment Period and the second for relapses occurring during the OLE Treatment Period. The relapse episodes for each participant will be recorded throughout the entire study. |
Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: UCB Cares, 001 844 599 2273
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MOG001
- 2021-000352-19 (Número EudraCT)
- 2023-509237-39 (Identificador de registro: EU Clinical Trials)
- U1111-1301-0122 (Outro identificador: Universal Trial Number (UTN))
- 2023 (Concessão/Contrato do NIH dos EUA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Prazo de Compartilhamento de IPD
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Critérios de acesso de compartilhamento IPD
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .